Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Japan Biotechs to Be Hit Hard by TSE Growth Market Reform, 26 Firms Fail to Reach Proposed Threshold
The Tokyo Stock Exchange (TSE) is considering changing the market-cap criteria for companies to list on its Growth Market, which targets startups, but this is expected to affect a significant portion of biotech firms currently traded in the section. The…
To read the full story
Related Article
BUSINESS
- Chugai Files Tecentriq in Adjuvant Use for MRD-Positive Bladder Cancer
January 29, 2026
- Otsuka’s Centanafadine Accepted for FDA Review with Priority Tag
January 28, 2026
- Sato Enters Smoking Cessation Market via Nicotinell Tie-Up with Dr. Reddy’s
January 27, 2026
- Top Court Rejects Samsung Challenge to Patent-Linkage Disclosures in Eylea Biosimilar Case
January 27, 2026
- Quviviq, Dayvigo Top 3 Promotion Channels in December: Intage
January 27, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…